Richard E. Uihlein - 24 Jan 2022 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Director, 10%+ Owner
Signature
Jack W. Callicutt
Issuer symbol
GALT
Transactions as of
24 Jan 2022
Net transactions value
+$35,000
Form type
4
Filing time
08 Feb 2022, 08:25:01 UTC
Previous filing
25 Jan 2022
Next filing
30 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common Stock Award $35,000 +17,677 +0.22% $1.98 7,936,677 24 Jan 2022 Direct F1
holding GALT Common Stock 27,710 24 Jan 2022 By Ed Uihlein Family Foundation F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 24 Jan 2022 Common Stock 40,000 $1.98 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022.
F2 The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
F3 The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
F4 The options vest 100% on December 31, 2022.